EUVIMEDEUVIMED entdecken
Open Access

Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes

Min-Hsiang Chuang, Jui-Yi Chen, Hsien-Yi Wang, Zheng-Hong Jiang, Vin-Cent Wu

JAMA Network Open · 12.08.2024 · 7 (8) · e2427258

DOI: 10.1001/jamanetworkopen.2024.27258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 12.08.2024. Verfasst von Min-Hsiang Chuang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cardiovascular Diseases, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 141-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Despite its demonstrated benefits in improving cardiovascular risk profiles, the association of tirzepatide with mortality and cardiovascular and kidney outcomes compared with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) remains unknown.

Objective

To investigate the association of tirzepatide with mortality and adverse cardiovascular and kidney outcomes compared with GLP-1 RAs in patients with type 2 diabetes. Design, Setting, and Participants This retrospective cohort study used US Collaborative Network of TriNetX data collected on individuals with type 2 diabetes aged 18 years or older initiating tirzepatide or GLP-1 RA between June 1, 2022, and June 30, 2023; without stage 5 chronic kidney disease or kidney failure at baseline; and without myocardial infarction or ischemic or hemorrhagic stroke within 60 days of drug initiation. Exposures Treatment with tirzepatide compared with GLP-1 RA. Main Outcomes and Measures The primary outcome was all-cause mortality, and secondary outcomes included major adverse cardiovascular events (MACEs), the composite of MACEs and all-cause mortality, kidney events, acute kidney injury, and major adverse kidney events. All outcomes were analyzed using Cox proportional hazards regression models.

Results

There were 14 834 patients treated with tirzepatide (mean [SD] age, 55.4 [11.8] years; 8444 [56.9%] female) and 125 474 treated with GLP-1 RA (mean [SD] age, 58.1 [13.3] years; 67 474 [53.8%] female). After a median (IQR) follow-up of 10.5 (5.2-15.7) months, 95 patients (0.6%) in the tirzepatide group and 166 (1.1%) in the GLP-1 RA group died. Tirzepatide treatment was associated with lower hazards of all-cause mortality (adjusted hazard ratio [AHR], 0.58; 95% CI, 0.45-0.75), MACEs (AHR, 0.80; 95% CI, 0.71-0.91), the composite of MACEs and all-cause mortality (AHR, 0.76; 95% CI, 0.68-0.84), kidney events (AHR, 0.52; 95% CI, 0.37-0.73), acute kidney injury (AHR, 0.78; 95% CI, 0.70-0.88), and major adverse kidney events (AHR, 0.54; 95% CI, 0.44-0.67). Treatment with tirzepatide was associated with greater decreases in glycated hemoglobin (treatment difference, −0.34 percentage points; 95% CI, −0.44 to −0.24 percentage points) and body weight (treatment difference, −2.9 kg, 95% CI, −4.8 to −1.1 kg) compared with GLP-1 RA. An interaction test for subgroup analysis revealed consistent results stratified by estimated glomerular filtration rate, glycated hemoglobin level, body mass index, comedications, and comorbidities. Conclusions and Relevance In this study, treatment with tirzepatide was associated with lower hazards of all-cause mortality, adverse cardiovascular events, acute kidney injury, and adverse kidney events compared with GLP-1 RA in patients with type 2 diabetes. These findings support the integration of tirzepatide into therapeutic strategies for this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Cardiovascular DiseasesHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedTreatment OutcomeGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatide

Substanzen

Hypoglycemic AgentsTirzepatideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-2 ReceptorGastric Inhibitory Polypeptide

Autor:innen und Institutionen

  • Division of Nephrology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
  • Department of Health and Nutrition, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.
  • Department of Sports Management, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.
  • Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei.

Zitieren

APA

Chuang, M. H., Chen, J. Y., Wang, H. Y., Jiang, Z. H., & Wu, V. C. (2024). Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes. JAMA Network Open, 7(8), e2427258. https://doi.org/10.1001/jamanetworkopen.2024.27258

Vancouver

Chuang MH, Chen JY, Wang HY, Jiang ZH, Wu VC. Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes. JAMA Network Open. 2024;7(8):e2427258. doi:10.1001/jamanetworkopen.2024.27258

BibTeX
@article{Chuang2024,
  author = {Chuang, Min-Hsiang and Chen, Jui-Yi and Wang, Hsien-Yi and Jiang, Zheng-Hong and Wu, Vin-Cent},
  title = {Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {8},
  pages = {e2427258},
  doi = {10.1001/jamanetworkopen.2024.27258}
}
Kostenlos starten →